Furthermore, genomic-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs, emphasizing the importance of molecular profiling in guiding treatment decisions for patients with thyroid cancer. Here, RET is linked to thyroid gland carcinoma.